GlassScriptPhysician profile
Michael T Siegel
NPI 1104915875
$708,469.20
in general payments reported to CMS, 2019-2025
40 companies · $132K in 2025
The $132K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184K · 2020: $46K · 2021: $32K · 2022: $103K · 2023: $105K · 2024: $107K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $308K · Food and Beverage: $16K · Travel and Lodging: $16K · Consulting Fee: $4,180 · Education: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $307,916.00 |
| Food and Beverage | $15,998.86 |
| Travel and Lodging | $15,582.02 |
| Consulting Fee | $4,180.00 |
| Education | $317.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $217,065.40 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Abbvie INC. | $116,784.62 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $103,031.86 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $64,884.04 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Janssen Scientific Affairs, LLC | $59,250.01 | 2019-2023 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $32,851.42 | 2019-2025 | Siliq, Duobrii, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $31,199.73 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $30,280.74 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $22,895.39 | 2019-2024 | Winlevi, Ilumya, Absorica Ld |
| Galderma Laboratories, L.P. | $17,327.48 | 2019-2025 | Nemluvio, Epiduo, Twyneo |
| Leo Pharma INC. | $3,979.36 | 2020-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $2,086.66 | 2019-2025 | |
| Zerigo Health, INC. | $1,200.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $972.99 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $926.02 | 2020-2025 | Spevigo, Cyltezo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $786.97 | 2022-2024 | Vtama |
| Amgen INC. | $475.69 | 2019-2025 | Otezla |
| Incyte Corporation | $441.93 | 2021-2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $404.31 | 2023-2025 | Zoryve |
| Pfizer INC. | $399.64 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $168.15 | 2021-2024 | |
| Vyne Pharmaceuticals INC. | $155.18 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $152.97 | 2023 | Idacio |
| Organon LLC | $152.31 | 2023-2025 | Hadlima, Vtama, Nexplanon |
| Allergan, INC. | $108.44 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $77.61 | 2019-2025 | |
| Almirall LLC | $70.87 | 2020-2024 | Seysara |
| Genentech USA, INC. | $49.36 | 2019-2021 | |
| Prugen, INC. Pharmaceuticals | $46.30 | 2020 | |
| Bausch & Lomb Americas INC. | $39.93 | 2025 | Vyzulta, Miebo |
| Paratek Pharmaceuticals, INC. | $24.67 | 2021 | |
| Blueprint Medicines Corporation | $24.56 | 2023 | Ayvakit |
| Melinta Therapeutics, LLC | $24.04 | 2019 | |
| Verrica Pharmaceuticals INC. | $24.03 | 2023 | Ycanth |
| Mylan Institutional INC. | $21.31 | 2023 | |
| Botanix Sb INC | $19.25 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $18.30 | 2019 | |
| Dermira, INC. | $17.91 | 2020 | |
| Journey Medical Corporation | $16.85 | 2022 | |
| Celgene Corporation | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.